Search

Your search keyword '"Lasser, Luc"' showing total 117 results

Search Constraints

Start Over You searched for: Author "Lasser, Luc" Remove constraint Author: "Lasser, Luc"
Sorry, I don't understand your search. ×
117 results on '"Lasser, Luc"'

Search Results

1. Viral clade is associated with severity of symptomatic genotype 3 hepatitis E virus infections in Belgium, 2010–2018

2. THU-092 Enrolling patients in ACLF trials-the need to increase ACLF awareness (DHELIVER trial)

Catalog

Books, media, physical & digital resources

3. A phase II study of human allogeneic liver-derived progenitor cell therapy for acute-on-chronic liver failure and acute decompensation

4. Doxorubicin-loaded nanoparticles for patients with advanced hepatocellular carcinoma after sorafenib treatment failure (RELIVE): a phase 3 randomised controlled trial

5. ACLF course profiles over screening period in the phase IIb DHELIVER study

6. Alcohol intake increases the risk of HCC in hepatitis C virus-related compensated cirrhosis: A prospective study

7. Intensive Enteral Nutrition Is Ineffective for Patients With Severe Alcoholic Hepatitis Treated With Corticosteroids

8. Viral clade is associated with severity of symptomatic genotype 3 Hepatitis E virus infections in Belgium, 2010-2018.

10. A phase II study of human allogeneic liver-derived progenitor cell therapy for acute-on-chronic liver failure and acute decompensation

11. Impact of intensive enteral nutrition in association with corticosteroids in the treatment of severe alcoholic hepatitis: a multicenter randomized controlled trial: 141

12. Behandeling van het 'buried bumper syndrome': case-report en overzicht van de literatuur

13. Stopping nucleos(t)ide analogue treatment in Caucasian hepatitis B patients after HBeAg seroconversion is associated with high relapse rates and fatal outcomes

14. FRI-550 - ACLF course profiles over screening period in the phase IIb DHELIVER study

16. Hepatitis E virus genotype 3 subtype dependent clinical outcomes in Belgium 2010–2018

18. Acute Portal Vein Thrombosis Unrelated to Cirrhosis: A Prospective Multicenter Follow-Up Study

19. Etiology, Management, and Outcome of the Budd-Chiari Syndrome

20. Safety and tolerability of liver-derived sem cells (Hepastem TM) infused in patients with acute on chronic liver failure (ACLF) or acute decompensation (AD) at risk of developing ACLF: a european phase I/IIa open labelled study

21. Safety and tolerability of liver-derived stem cells (HepaStem) infused in patients with acute-on-chronic liver failure or acute decompensation: a European phase I/IIa open-labelled study

22. Safety and tolerability of liver-derived sem cells (Hepastem TM) infused in patients with acute on chronic liver failure (ACLF) or acute decompensation (AD) at risk of developing ACLF: a european phase I/IIa open labelled study

23. New Concepts in Liver Regeneration Mechanisms in Human Severe Alcoholic Steatohepatitis

24. Doxorubicin-loaded nanoparticles for patients with advanced hepatocellular carcinoma after sorafenib treatment failure (RELIVE): a phase 3 randomised controlled trial

25. FRI-221-Management of drug-drug interactions in chronic hepatitis C patients treated with second generation direct acting antivirals in Belgium

26. Antithrombotic treatment with direct-acting oral anticoagulants in patients with splanchnic vein thrombosis and cirrhosis

27. Cessation of Nucleos(t)ide Analogue treatment after HBeAg seroconversion is associated with a 4-fold increased risk of relapse in cirrhotic compared to non-cirrhotic patients

28. GS-16-Safety and tolerability of liver-derived stem cells (HepaStem) infused in patients with acute-on-chronic liver failure or acute decompensation: a European phase I/IIa open-labelled study

29. Sofosbuvir in Combination with Simeprevir +/- Ribavirin in Genotype 4 Hepatitis C Patients with Advanced Fibrosis or Cirrhosis: A Real-World Experience from Belgium

30. Sofosbuvir in combination with simeprevir +/- ribavirin in genotype 4 hepatitis C patients with advanced fibrosis or cirrhosis: A real-world experience from Belgium

31. SAT409 - Hepatitis E virus genotype 3 subtype dependent clinical outcomes in Belgium 2010–2018

32. Sofosbuvir in Combination with Simeprevir +/- Ribavirin in Genotype 4 Hepatitis C Patients with Advanced Fibrosis or Cirrhosis: A Real-World Experience from Belgium

33. Alcohol intake increases the risk of HCC in hepatitis C virus-related compensated cirrhosis: A prospective study.

34. Sofosbuvir in combination with simeprevir plus /- ribavirin in genotype 4 hepatitis C patients with advanced fibrosis or cirrhosis: real-life experience from Belgium

35. Ethnic epidemiological profiles and antiviral therapy among patients infected with hepatitis C virus genotype 4 :A multicenter study from Belgium

36. A lady with NASH and choreoathetosis

37. Characteristics, treatment, and virologic responses of chronic hepatitis C patients treated with peginterferon alfa-2a and ribavirin in Belgium: A sub-analysis of the PROPHESYS study

38. DRESS syndrome à la phénytoïne

39. Characteristics, treatment, and virologic responses of chronic hepatitis C patients treated with peginterferon alfa-2a and ribavirin in Belgium: A sub-analysis of the PROPHESYS study

40. Impact of intensive enteral nutrition in association with corticosteroids in the treatment of severe alcoholic hepatitis: a multicenter randomized controlled trial

41. Response of black African patients with hepatitis C virus genotype 4 to treatment with peg-interferon and ribavirin

42. High prevalence of advanced fibrosis in association with the metabolic syndrome in a Belgian prospective cohort of NAFLD patients with elevated ALT. results of the Belgian NAFLD registry

43. Upper gastrointestinal bleeding related to emphysematous cholecystitis due to Clostridium perfringens.

44. Clinical trial: A randomized trial of pegylated-interferon-α-2a plus ribavirin with or without amantadine in treatment-naïve or relapsing chronic hepatitis C patients

45. Etiology, management, and outcome of the Budd-Chiari syndrome.

46. Enteral nutrition with or without N-acetyslcysteine in the treatment of severe acute alcoholic hepatitis: a randomized, multicenter, controlled trial

47. Enteral nutrition with or without N-acetyslcysteine in the treatment of severe acute alcoholic hepatitis: a randomized, multicenter, controlled trial

48. Long-term (7-year-) treatment with lamivudine monotherapy in HBV-associated glomerulonephritis

49. What is the optimal duration of therapy in patients with hepatitis C genotype 2 or 3 infection? A review

50. L'hépatite C chez la femme en âge de procréer. Etat de la question